1. Alisporivir for use in treating patients infected with hepatitis C virus, characterized in chtoalisporivir administered in an amount of from about 400 to about 600 mg twice a sutki.2. Alisporivir for use according to Claim. 1, characterized in that alisporivir administered in combination with standard treatment or direct antiviral agent deystviya.3. Alisporivir for use according to Claim. 1 or 2, characterized in that alisporivir administered for 24, 48 or 72 nedel.4. Alisporivir for use according to claim. 2, where the standard treatment with a combination of interferon ribavirinom.5. Alisporivir for use according to claim. 4, wherein said interferon is pegylated interferon alpha-2a, and is administered in an amount of 180 micrograms once a nedelyu.6. Alisporivir for use according to claim 2, wherein said means of direct action is ANA598.7. A method for treating patients infected with Hepatitis C virus comprising administering alisporivira in an amount from about 400 to about 600 mg twice a day for 24, 48 or 72 nedel.8. Application alisporivira in the manufacture of a medicament for the treatment of patients infected with hepatitis C virus, characterized in chtoalisporivir administered in an amount of from about 400 to about 600 mg twice a day for 24, 48 or 72 weeks, and optionally wherein alisporivir administered in combination standard therapy or direct deystviya.9 means. Combination alisporivira and standard treatment or direct antiviral agents for use in treating a patient infected with hepatitis C, characterized in that alisporivir administered in an amount of from about 400 to about 800 mg twice a day for d1. Алиспоривир для применения в лечении пациентов, инфицированных вирусом гепатита C, характеризующийся тем, чтоалиспоривир вводят в количестве от около 400 до около 600 мг два раза в сутки.2. Алиспоривир для применения по п. 1, отличающийся тем, что алиспоривир вводят в комбинации со стандартным лечением или противовирусным средством прямого действия.3.
